Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 6/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.57 |
| ▸ | RARB | P10826 | 2/20 | 0.55 |
| ▸ | MMP1 | P03956 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29004517 | 0.95 | TP53 (0.67) | LSSMAPTTP53TSHRPLA2G4B | |
| SCHEMBL17925369 | 0.93 | MAPT (0.68) | LSSMAPTMEN1LMNAMAPK1 | |
| SCHEMBL8769969 | 0.91 | TP53 (0.68) | MEN1KMT2ATP53TSHRPLA2G4B | |
| SCHEMBL17203727 | 0.87 | TP53 (0.74) | TP53TSHRPLA2G4BRARBL3MBTL1 | |
| SCHEMBL16561565 | 0.87 | MAPT (0.57) | LSSMAPTMEN1LMNAMAPK1 | |
| SCHEMBL6340083 | 0.86 | TP53 (0.58) | MEN1KMT2ATP53TSHRPLA2G4B | |
| SCHEMBL533825 | 0.86 | TP53 (0.77) | TP53TSHRPLA2G4BRARBL3MBTL1 | |
| SCHEMBL18302060 | 0.86 | TP53 (0.77) | TP53TSHRPLA2G4BRARBL3MBTL1 | |
| SCHEMBL1623628 | 0.86 | TP53 (0.77) | TP53TSHRPLA2G4BRARBL3MBTL1 | |
| SCHEMBL6705357 | 0.86 | TP53 (0.77) | TP53TSHRPLA2G4BRARBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | LUMINIDE | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | APEH, PAH, ALAD | LSS 409/4885MAPT 2279/4885MEN1 2928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.